Parametric Portfolio Associates LLC lowered its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 16.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 297,513 shares of the biopharmaceutical company’s stock after selling 56,498 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.13% of Alexion Pharmaceuticals worth $29,138,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. California State Teachers Retirement System grew its position in shares of Alexion Pharmaceuticals by 8.8% in the 3rd quarter. California State Teachers Retirement System now owns 389,638 shares of the biopharmaceutical company’s stock valued at $38,161,000 after purchasing an additional 31,474 shares during the period. Phoenix Holdings Ltd. acquired a new position in Alexion Pharmaceuticals during the 3rd quarter worth approximately $18,026,000. Andra AP fonden grew its stake in shares of Alexion Pharmaceuticals by 24.0% during the 3rd quarter. Andra AP fonden now owns 27,900 shares of the biopharmaceutical company’s stock worth $2,733,000 after acquiring an additional 5,400 shares in the last quarter. Stifel Financial Corp grew its stake in shares of Alexion Pharmaceuticals by 11.7% during the 3rd quarter. Stifel Financial Corp now owns 110,646 shares of the biopharmaceutical company’s stock worth $10,913,000 after acquiring an additional 11,571 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at approximately $2,245,000. Institutional investors own 91.60% of the company’s stock.

NASDAQ:ALXN opened at $114.05 on Wednesday. The company has a quick ratio of 3.45, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. The stock’s 50 day moving average price is $107.89 and its two-hundred day moving average price is $113.10. The firm has a market capitalization of $25.21 billion, a price-to-earnings ratio of 16.09, a P/E/G ratio of 1.08 and a beta of 1.67. Alexion Pharmaceuticals, Inc. has a 12-month low of $92.56 and a 12-month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period last year, the firm posted $2.02 earnings per share. The business’s revenue was up 23.0% on a year-over-year basis. Equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 9.43 EPS for the current year.

Several research analysts recently commented on the stock. Oppenheimer reduced their target price on shares of Alexion Pharmaceuticals from $165.00 to $150.00 in a report on Thursday, October 24th. Morgan Stanley lowered their price target on shares of Alexion Pharmaceuticals from $177.00 to $170.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. William Blair assumed coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 26th. They set an “outperform” rating and a $146.00 price target on the stock. BMO Capital Markets initiated coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 12th. They set an “outperform” rating and a $149.00 price objective for the company. Finally, Leerink Swann set a $157.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $156.37.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: What is FinTech?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.